Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 2/20 | 0.51 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 2/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.43 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6799990 | 1.00 | ITGA4 (0.51) | ITGA4ITGB7MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6827938 | 0.89 | ITGA4 (0.46) | ITGA4ITGB7MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6827943 | 0.89 | ITGA4 (0.46) | ITGA4ITGB7MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1491432 | 0.83 | CYP2D6 (0.47) | ITGA4ITGB7KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL1491427 | 0.83 | CYP2D6 (0.47) | ITGA4ITGB7KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL7281801 | 0.82 | MEN1 (0.52) | ITGA4ITGB7MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30841268 | 0.82 | ITGA4 (0.45) | ITGA4ITGB7MEN1KMT2AALDH1A1 | |
| SCHEMBL2387240 | 0.82 | ITGA4 (0.52) | ITGA4ITGB7MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6795785 | 0.81 | PTPRB (0.51) | — | |
| SCHEMBL6798124 | 0.81 | PTPRB (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004074238-A1 | PHENETHYLAMINO SULFAMIC ACIDS | THE PROCTER & GAMBLE COMPANY (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167183-A1 | Phenethylamino sulfamic acids | THE PROCTER & GAMBLE COMPANY | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167183-A1 | Phenethylamino sulfamic acids | PTPRM, PTPRS, PTPRE | ITGA4 4015/4885ITGB7 4071/4885MEN1 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.